It is used with another medication, such as chloroquine, that kills the parasites in the bloodstream.There is a need to determine whether or not tafenoquine kills the numerous, non-circulating asexual P. vivax parasites that are now known to occur in the spleen, bone marrow, and possibly elsewhere in chronic infections. Chemistry
Tafenoquine contains a stereocenter and consists of two enantiomers. This is a mixture of (R) - and the (S) - Form:

History
Tafenoquine was approved for medical use in Australia and in the United States in 2018. Tafenoquine was given an orphan drug designation and was granted breakthrough therapy status in 2013 in the United States. Society and culture
One version is made by GlaxoSmithKline. While another is made by 60 Degrees Pharmaceutical. Names
Etaquine was a generic name proposed by WRAIR, and subsequently rejected by CDER.Trade names

Kozenis (Australia)
Kodatef (Australia)
Arakoda (USA), Krintafel (USA)

References
External links
"Tafenoquine". Drug Information Portal. U.S. National Library of Medicine.
It is used in combination with ethinylestradiol in birth control pills and in combination with estradiol in menopausal hormone therapy. Available forms
Norgestimate is available only in combination with the estrogens ethinylestradiol and estradiol. These formulations are for use by mouth and are indicated specifically for hormonal contraception and menopausal hormone therapy. Norgestimate is not available on its own (i.e., as a standalone medication). Contraindications
Side effects
Norgestimate has mostly been studied in combination with an estrogen, so the side effects of norgestimate specifically or on its own have not been well-defined.Side effects associated with the combination of ethinylestradiol and norgestimate in premenopausal women, with greater than or equal to 2% incidence over up to 24 menstrual cycles, include headache/migraine (33%), abdominal/gastrointestinal pain (7.8%), vaginal infection (8.4%), vaginal discharge (6.8%), breast issues (including breast pain, discharge, and enlargement) (6.3%), mood disorders (including depression and mood alterations) (5.0%), flatulence (3.2%), nervousness (2.9%), and rash (2.6%).Side effects associated with the combination of estradiol and norgestimate in postmenopausal women, with greater than or equal to 5% incidence over one year, include headache (23%), upper respiratory tract infection (21%), breast pain (16%), back pain (12%), abdominal pain (12%), flu-like symptoms (11%), arthralgia (9%), vaginal bleeding (9%), dysmenorrhea (8%), sinusitis (8%), vaginitis (7%), pharyngitis (7%), fatigue (6%), pain (6%), nausea (6%), viral infection (6%), flatulence (5%), tooth disorder (5%), myalgia (5%), dizziness (5%), depression (5%), and coughing (5%).